Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Capital Expenditures (2018 - 2025)

Entera Bio has reported Capital Expenditures over the past 8 years, most recently at $27000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 800.0% year-over-year to $27000.0, compared with a TTM value of $107000.0 through Dec 2025, up 3466.67%, and an annual FY2025 reading of $107000.0, up 3466.67% over the prior year.
  • Capital Expenditures came in at $27000.0 for Q4 2025, down from $43000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $43000.0 in Q3 2025 to a low of $1000.0 in Q2 2023.
  • Median Capital Expenditures over the past 5 years was $9000.0 (2021), compared with a mean of $13642.9.
  • The sharpest move saw Capital Expenditures tumbled 94.74% in 2023, then surged 800.0% in 2025.
  • Over 5 years, Capital Expenditures stood at $10000.0 in 2021, then crashed by 70.0% to $3000.0 in 2022, then soared by 66.67% to $5000.0 in 2023, then crashed by 40.0% to $3000.0 in 2024, then surged by 800.0% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Capital Expenditures are $27000.0 (Q4 2025), $43000.0 (Q3 2025), and $29000.0 (Q2 2025).